Additionally, inhibiting IL-6/signal transducer and activator of transcription 3 (STAT3) signaling has been found to reduce I148M variant-mediated susceptibility to NAFLD [141]. The gene discussed is STAT3; the disease is metabolic dysfunction-associated steatotic liver disease.